文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

牛磺罗定-枸橼酸封管液预防成人中性粒细胞减少血液肿瘤患者中心静脉导管感染:TAURCAT随机双盲安慰剂对照试验

Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
PubMed 文献 · Trials · 2018-05-02

TAURCAT是一项前瞻性、多中心、随机、双盲、平行、优效性、安慰剂对照试验,拟纳入预期出现长时间中性粒细胞减少(>7天)且置入非隧道式中心静脉导管的血液肿瘤患者,比较牛磺罗定-枸橼酸-肝素封管液与单纯肝素(安慰剂)预防导管感染的疗效。主要终点为导管接头细菌定植,次要终点包括导管相关血流感染发生率、导管移除、不良事件及30天病死率。

要点

  • 牛磺罗定-枸橼酸封管液可能降低高危中性粒细胞减少血液肿瘤患者的导管接头细菌定植。
  • 主要终点为导管接头细菌定植,次要终点包括CRBSI发生率、导管移除、不良事件和30天病死率。
  • 既往在癌症患者中的试验结果存在争议,且缺乏成人高危中性粒细胞减少人群的数据。

核心结论

  • 该试验旨在验证牛磺罗定-枸橼酸封管液在预防中性粒细胞减少血液肿瘤患者导管感染方面优于安慰剂。

研究设计与样本

  • 前瞻性、多中心、随机、双盲、平行、优效性、安慰剂对照试验。
  • 拟纳入预期中性粒细胞减少持续>7天且置入非隧道式中心静脉导管的血液肿瘤患者。
  • 研究组接受牛磺罗定-枸橼酸-肝素封管液,对照组接受单纯肝素(安慰剂)。

关键数值与推荐

  • 主要终点为导管接头细菌定植。
  • 次要终点包括导管相关血流感染发生率、导管移除、不良事件及30天病死率。

临床怎么用

  • 若试验假设成立,可为高危中性粒细胞减少患者采用牛磺罗定-枸橼酸封管液预防CRBSI提供证据。

局限性

  • 既往在癌症患者中的试验结果存在争议,且缺乏成人及高危中性粒细胞减少人群的数据。
  • 既往研究存在导管类型(隧道式或输液港)及封管方案信息不足等局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a non-antibiotic agent with broad-spectrum antimicrobial activity, which has been used as a lock solution to prevent CRBSI in some settings. However, little is known about its usefulness in high-risk adult neutropenic patients with cancer. This prospective randomised clinical trial aims to test the hypothesis that taurolidine-citrate lock solution is more effective than placebo for preventing catheter infection in neutropenic haematological patients. METHODS: This study is a prospective, multicentre, randomised, double-blinded, parallel, superiority, placebo-controlled trial. Patients with haematological cancer who are expected to develop prolonged neutropenia (> 7 days) and who have a non-tunnelled CVC implanted will be randomised to receive prophylactic taurolidine-citrate-heparin solution using a lock technique (study group) or heparin alone (placebo group). The primary endpoint will be bacterial colonisation of the CVC hubs. The secondary endpoints will be the incidence of CRBSI, CVC removal, adverse events, and 30-day case-fatality rate. DISCUSSION: The lock technique is a preventive strategy that inhibits bacterial colonisation in the catheter hubs, which is the initial step of endoluminal catheter colonisation and the development of infection. Taurolidine is a nontoxic agent that does not develop antibiotic resistance because it acts as an antiseptic rather than an antibiotic. Taurolidine has shown controversial results in the few trials conducted in cancer patients. These studies have important limitations due to the lack of data on adult and/or high-risk neutropenic patients, the type of catheters studied (tunnelled or ports), and the lack of information regarding the intervention (e.g. dwelling of the solution, time, and periodicity of the lock technique). If our hypothesis is proven, the study could provide important solid evidence on the potential usefulness of this preventive procedure in a population at high risk of CRBSI, in whom this complication may significantly impair patient outcome. TRIAL REGISTRATION: ISRCTN, ISRCTN47102251 . Registered on 9 September 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gudiol C, Nicolae S, Royo-Cebrecos C, et al. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT). Trials. 2018. PMID: 29720244. doi:10.1186/s13063-018-2647-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。